Our Facilities
Our flexible, state-of-the-art, fit-for-service facilities allow the Coriolis Pharma team to serve the comprehensive drug product development, analytical service and manufacturing service needs of wide-ranging biotherapeutic modalities under R&D and GMP conditions.
Martinsried, Germany
Headquarters and Primary Operations
Our 6-floor main facility houses our primary analytical lab, storage, non-GMP manufacturing and lyophilization capabilities.
Our 6-floor main facility houses our primary analytical lab, storage, non-GMP manufacturing and lyophilization capabilities.
Facility Highlights
- 3,600+ sqm R&D and GMP lab space under biosafety levels 1 and 2
- 200+ analytical devices, including analytical ultracentrifugation (AUC)
- Lyophilization Center
- HPLC Center Lab space with movable benches for increased flexibility
- Automated filling line and manual filling capacities under aseptic conditions
- 3,600+ sqm R&D and GMP lab space under biosafety levels 1 and 2
- 200+ analytical devices, including analytical ultracentrifugation (AUC)
- Lyophilization Center
- HPLC Center Lab space with movable benches for increased flexibility
- Automated filling line and manual filling capacities under aseptic conditions
Featured Services Under R&D and GMP
- Developability assessment
- Preformulation screening
- Formulation development
- Stability studies
- In-use studies
- Particle analytics
- Lyophilization process development
- Comparability studies
- Release testing
- Tox study manufacturing
- Developability assessment
- Preformulation screening
- Formulation development
- Stability studies
- In-use studies
- Particle analytics
- Lyophilization process development
- Comparability studies
- Release testing
- Tox study manufacturing
Martinsried, Germany
Advanced Therapy and Medical Products (ATMPs) Facility
To meet the rapidly growing needs of gene and cell therapy developers, Coriolis debuted its ATMP facility in Q1 2022.
To meet the rapidly growing needs of gene and cell therapy developers, Coriolis debuted its ATMP facility in Q1 2022.
Facility Highlights
- 1,400+ sqm lab space under biosafety level 2
- 60+ analytical devices
- Particle Identification Center
- Lyophilization line
- Center for Cell Culture
- 1,400+ sqm lab space under biosafety level 2
- 60+ analytical devices
- Particle Identification Center
- Lyophilization line
- Center for Cell Culture
Featured Services Under R&D and GMP
- Formulation development
- Stability studies
- In-use studies
- Virus titration and quantification
- Particle characterization and identification
- Comparability studies
- Lyophilization development
- Formulation development
- Stability studies
- In-use studies
- Virus titration and quantification
- Particle characterization and identification
- Comparability studies
- Lyophilization development
Ann Arbor, Michigan, USA
U.S. Commercial Organization
Further supporting our growth in North America, our project management and business development team in the United States facilitates seamless services with our German operations.
Further supporting our growth in North America, our project management and business development team in the United States facilitates seamless services with our German operations.
